Transcriptomics

Dataset Information

0

Blocking 6PGD restricts immunosuppression driven by the innate immune response in cancer


ABSTRACT: The pentose phosphate pathway (PPP) has always been relegated to the background of cellular metabolism, but our research identifies its unique and provocative influence on cell function, specifically in myeloid-derived suppressor cells (MDSCs). We’ve uncovered that 6-phosphogluconate dehydrogenase (6PGD), a rate limiting enzyme in this pathway, is not just a metabolic enzyme but a crucial determinant of MDSC behavior. While the IL-6/STAT3 axis propels 6PGD activity, it also empowers MDSCs to exert their immune-suppressive prowess. When we disrupt 6PGD – either through genetic knockout or pharmacological inhibition – an astonishing transformation occurs. The accumulation of 6-phosphogluconate (6PG) sets off a cascade involving JNK1-IRS-1 interaction and PI3K-AKT-pDRP1 signaling pathway, triggering mitochondrial fragmentation and dismantling oxidative phosphorylation (OXPHOS). This change in metabolism doesn’t just disrupt MDSC function; it transforms it stimulatory, leading to a strong anti-tumor response and making anti-PD1 therapies much more effective. Our results suggest we need to completely rethink the role of the PPP in cell function, with 6PGD emerging as a key target that could change the future of cancer immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE278674 | GEO | 2025/11/12

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-02-13 | E-GEOD-42223 | biostudies-arrayexpress
2013-02-13 | GSE42223 | GEO
2012-07-31 | E-GEOD-38933 | biostudies-arrayexpress
2012-08-01 | GSE38933 | GEO
2020-08-01 | GSE144649 | GEO
2021-11-03 | PXD023337 | Pride
2021-01-01 | GSE163399 | GEO
2017-11-17 | PXD006204 | Pride
2015-02-03 | E-GEOD-65517 | biostudies-arrayexpress
2010-06-16 | E-GEOD-21927 | biostudies-arrayexpress